Single high-dose treatment with glucosaminyl-muramyl dipeptide is ineffective in treating ankylosing spondylitis

Olga V. Britanova, Dmitriy B. Staroverov, Anna V. Chkalina, Alexei A. Kotlobay, Ekaterina S. Zvezdova, Anna G. Bochkova, Dmitriy M. Chudakov

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Earlier studies have shown that high doses of TNF-alpha increase apoptosis in human autoimmune T-cell clones. Based on these studies, a treatment approach was proposed to reduce or eliminate autoimmune T cells in patients with type 1 diabetes using drugs that temporarily elevate TNF levels. Here, we report the treatment of ankylosing spondylitis patient with a single high oral dose of Likopid (glucosaminyl-muramyl dipeptide), which aimed at increasing the levels of TNF-alpha in order to induce apoptosis of autoreactive T cells. The flow cytometric analysis of blood samples collected before and after treatment demonstrated massive elimination of CD8 + T cells. However, the treatment did not result in any notable therapeutic effect, and real-time PCR analysis demonstrated that stably expanded T-cell clones that were earlier tracked in this patient were unaffected. This report suggests that the controversial approach to eliminate autoimmune T-cell clones through overstimulation is not effective in treating ankylosing spondylitis.

Original languageEnglish
Pages (from-to)1101-1103
Number of pages3
JournalRheumatology International
Volume31
Issue number8
DOIs
Publication statusPublished - Aug 2011
Externally publishedYes

Keywords

  • Ankylosing spondylitis
  • Autoimmune T cells
  • Likopid
  • Muramyl dipeptide
  • NOD2 receptor
  • TNF-alpha level

Fingerprint

Dive into the research topics of 'Single high-dose treatment with glucosaminyl-muramyl dipeptide is ineffective in treating ankylosing spondylitis'. Together they form a unique fingerprint.

Cite this